284 related articles for article (PubMed ID: 30827472)
1. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
[TBL] [Abstract][Full Text] [Related]
2. [Fever and thin-walled cavitary lung lesions].
Ramos A; Daza R; Alvarez-Espejo T; Guzmán MF
Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):363-4. PubMed ID: 19419797
[No Abstract] [Full Text] [Related]
3. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.
Santin M; Dorca J; Alcaide F; Gonzalez L; Casas S; Lopez M; Guerra MR
Eur Respir J; 2009 Jan; 33(1):148-52. PubMed ID: 19118226
[TBL] [Abstract][Full Text] [Related]
4. Clinical and epidemiological characteristics of M. kansasii pulmonary infections from Rio de Janeiro, Brazil, between 2006 and 2016.
Goldenberg T; Gayoso R; Mogami R; Lourenço MC; Ramos JP; Carvalho LD; Dalcolmo MP; Mello FCQ
J Bras Pneumol; 2020; 46(6):e20190345. PubMed ID: 32696934
[TBL] [Abstract][Full Text] [Related]
5. Temporal interferon-gamma release response to Mycobacterium kansasii infection in an anorexia nervosa patient.
Cosson MA; Bertrand JB; Martin C; Veziris N; Picard C; Goulvestre C; Coignard S; Benoit JP; Silvera S; Moro MR; Poyart C; Morand PC
J Med Microbiol; 2012 Nov; 61(Pt 11):1617-1620. PubMed ID: 22859583
[TBL] [Abstract][Full Text] [Related]
6. Mycobacterium kansasii pulmonary diseases in Korea.
Yim JJ; Park YK; Lew WJ; Bai GH; Han SK; Shim YS
J Korean Med Sci; 2005 Dec; 20(6):957-60. PubMed ID: 16361804
[TBL] [Abstract][Full Text] [Related]
7. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
[TBL] [Abstract][Full Text] [Related]
8. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.
Jeong BH; Jeon K; Park HY; Kim SY; Lee KS; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Am J Respir Crit Care Med; 2015 Jan; 191(1):96-103. PubMed ID: 25393520
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial.
Zweijpfenning SMH; Aarnoutse R; Boeree MJ; Magis-Escurra C; Stemkens R; Geurts B; van Ingen J; Hoefsloot W
Chest; 2024 May; 165(5):1082-1092. PubMed ID: 38040054
[TBL] [Abstract][Full Text] [Related]
10. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.
Zweijpfenning S; Kops S; Magis-Escurra C; Boeree MJ; van Ingen J; Hoefsloot W
Respir Med; 2017 Oct; 131():220-224. PubMed ID: 28947034
[TBL] [Abstract][Full Text] [Related]
11. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii.
Ahn CH; Lowell JR; Ahn SS; Ahn SI; Hurst GA
Am Rev Respir Dis; 1983 Dec; 128(6):1048-50. PubMed ID: 6650978
[TBL] [Abstract][Full Text] [Related]
12. Rifampin-resistant Mycobacterium kansasii.
Wallace RJ; Dunbar D; Brown BA; Onyi G; Dunlap R; Ahn CH; Murphy DT
Clin Infect Dis; 1994 May; 18(5):736-43. PubMed ID: 8075262
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea.
Park HK; Koh WJ; Shim TS; Kwon OJ
Yonsei Med J; 2010 Jul; 51(4):552-6. PubMed ID: 20499421
[TBL] [Abstract][Full Text] [Related]
14. [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].
Wagner D; Lange C
Dtsch Med Wochenschr; 2020 Aug; 145(16):1145-1151. PubMed ID: 32791550
[TBL] [Abstract][Full Text] [Related]
15. [Nontuberculous Mycobacterial Pulmonary Disease - The New ATS/ERS/ESCMID/IDSA Guideline].
Wagner D; Lange C
Pneumologie; 2020 Nov; 74(11):773-779. PubMed ID: 33202438
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy.
Sauret J; Hernández-Flix S; Castro E; Hernández L; Ausina V; Coll P
Tuber Lung Dis; 1995 Apr; 76(2):104-8. PubMed ID: 7780090
[TBL] [Abstract][Full Text] [Related]
17. [Nontuberculous mycobacterial infections of the lung].
Latshang TD; Lo Cascio CM; Russi EW
Ther Umsch; 2011 Jul; 68(7):402-6. PubMed ID: 21728159
[TBL] [Abstract][Full Text] [Related]
18. Clinical and radiological features of Mycobacterium kansasii and other NTM infections.
Matveychuk A; Fuks L; Priess R; Hahim I; Shitrit D
Respir Med; 2012 Oct; 106(10):1472-7. PubMed ID: 22850110
[TBL] [Abstract][Full Text] [Related]
19. [THE GENETIC EXAMINATION OF BRONCHIAL LAVAGE ENABLES THE PROMPT DIAGNOSIS OF PULMONARY MYCOBACTERIUM KANSASII--A CASE REPORT].
Mori M; Ageshio F; Kagawa H; Oshitani Y; Fujikawa T; Saito H; Sako H; Yano Y; Kitada S; Maekura R
Kekkaku; 2015 Aug; 90(8):619-23. PubMed ID: 26665518
[TBL] [Abstract][Full Text] [Related]
20. Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.
Srivastava S; Boorgula GD; Wang JY; Huang HL; Howe D; Gumbo T; Heysell SK
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0232021. PubMed ID: 35315686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
